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Introduction: Composite tissue allotransplantation is a newly emerged ﬁeld of trans-
plantation. Shock wave technology has already been used in the treatment of urologic
and orthopedic disorders. Recent studies demonstrated a suppression of the early proin-
ﬂammatory immune response. Methods: 50 allogeneic hindlimb transplantations were
performed on rats in 5 different groups. Group A (n = 10), (Lewis → Brown-Norway)
received 500 impulses of extracorporeal shock wave. Groups B, C, D, and E served
as control groups with group B (n = 10) receiving no immunosuppression, group C
(n = 10) receiving FK506 and prednisolone, group D (n = 10) receiving no immunosup-
pression with isograft transplantations (Brown-Norway → Brown-Norway) and group
E receiving 500 impulses of extracorporeal shock wave on the contralateral hindlimb.
Results: Rejection of the allogeneic hindlimb occurred on average 7.12 days after
transplantation in group A (extracorporeal shock wave). Rejection was signiﬁcantly de-
layed compared to the control groups B (no immunosuppression) and E (contralateral
hindlimb), where rejection of the allogeneic hindlimb occurred on average 5.49 and 5.6
days after transplantation (t test, P <. 01). No rejection was seen in groups C and D.
Conclusions: For the ﬁrst time, shock waves have been applied in a composite tissue
allotransplantation model and resulted in a signiﬁcant immunosuppressive effect. These
promising ﬁrst results have showed that shock wave treatment is clinically relevant
in composite tissue allotransplantation and justify subsequent research to improve the
experimental and clinical outcome.
Composite tissue allotransplantation (CTA) is an emerging ﬁeld of transplantation
that offers a potential treatment for complex tissue defects after traumatic loss or tumor
resection and for the repair of congenital abnormalities. Since CTA of hand, face, and other
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tissues is a clinical reality, CTA has gained importance as an alternative reconstruction
procedure. However, all these procedures are not routinely performed because most CTAs
compared to solid organ transplantation are non–life saving operations. Consequently,
there has been a wide debate about whether the beneﬁt of CTA justiﬁes the risks of lifelong
immunosuppressive therapies, as they remain nonspeciﬁc to the type of donor and still bear
signiﬁcant risks of serious side effects. These side effects include an increased incidence
of neoplasms, organ toxicity, and opportunistic infections.
The most appealing solution to this problem would be the induction of immuno-
logic tolerance, deﬁned as lifelong, donor-speciﬁc unresponsiveness without the need for
immunosuppressive drugs.
In the past 10 years, it has been shown that it is possible to achieve prolonged hand
allograft survival with a good functional outcome, superior to that obtained by prostheses,
with mainly the same triple drug immunosuppressive regime used routinely in kidney
transplants to control rejection of transplanted hands.1-8 These intermediate long-term
results have far exceeded expectations both from an immunological and a functional point
of view. Improvement of immunotherapy with the eventual aim of tolerance induction
therefore continues to be a highly desirable goal in both organ and CTA.
Until now, the effect of extracorporeal shock waves (ESW) has not been investigated
in a CTA. There is very limited published information as to the safety and complications
of ESW treatment in conjunction with CTA.
Shock waves are high-energy acoustic waves, generated through an electrohydraulic
method in this case, that result from high voltage explosion and vaporization.9,10 Since its
successful introduction in 1980 for fragmentation of kidneys stone, ESW has been adapted
for many other clinical indications such as musculoskeletal disorders (nonunion of long
bone fractures, calcifying tendonitis).11-14 Previous animal and clinical studies found that
during shock wave treatment various angiogenic factors are being released.15-26 Aicher
et al27 demonstrated that low-energy ESW treatment improves recruitment of circulating
endothelialprogenitorcellsviaenhancedexpressionofchemoattractantfactorsinhindlimb
ischemia in a rat model. Recently published studies showed that early proangiogenic and
anti-inﬂammatory effects of ESW promote tissue revascularization and wound healing
by augmenting angiogenesis and suppressing proinﬂammatory immune response.28,29 The
potentialofESWtoaugmentangiogenesisandsuppressproinﬂammatoryimmuneresponse
hasarousedinterestaboutitsuseinotherprocedures.Theaimofthisstudywastoinvestigate
the effect of ESW in a rodent in vivo model of CTA (hindlimb transplantation).
MATERIAL AND METHODS
Animals
Male Lewis (LW) (RT 1l) rats (Charles River WIGA, Sulzfeld, Germany) (160-180 g,
7-11 weeks old) were used as hindlimb donors. Brown-Norway (BN) (RT 1n) rats (Charles
River WIGA, Sulzfeld, Germany) (220-240 g, 11-15 weeks old) served as recipients. This
combination represents a very strong histocompatibility mismatch.
The experimental protocol was approved by a review committee of the state of Baden-
Wuerttemberg, Germany, in accordance to the guidelines of the German Animal Welfare
Act. Surgical procedures were performed under standard aseptic conditions.
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In vivo transplantation model
In all experiments anaesthesia was induced and maintained by an intraperitoneal injection
of sodium pentobarbital (50 mg/kg body weight) (Narcoren; Merial GmbH, Germany) and
an intramuscular injection of ketamine hydrochloride (30 mg/kg body weight) (Ketanest S;
Parke-Davis GmbH, Berlin, Germany). After initial shaving, the left hindlimb of the donor
rat was prepared under aseptic conditions. Skin, muscle, and bone were cut at mid thigh
level,thefemoralvesselswereﬁrstdissectedincontinuitywithligationofbranchingvessels.
Heparin (5000 U) was injected into the penile vein. The femoral artery was cannulated and
the hindlimb perfused with ringer solution containing 2 U/mL heparin for 10 minutes.
Thereafter the femoral vessels were divided.
The hindlimbs of the BN rats were amputated in the way described earlier. The donor
and recipient femurs were then joined by the use of a 1.0 or 1.2 mm intramedullary
K-wire. The femoral artery and vein were anastomosed using standard microsurgical tech-
niques with 10-0 nylon sutures. After anastomosis, the ventral and dorsal muscle groups
of the thigh were approximated and the skin was sutured. Ischemia time was approximated
at 2 hours. Postoperatively, the recipients received 5 mL of 0.9% NaCl subcutaneously
for ﬂuid substitution. As a pain medication, buprenorphine (Temgesic; Schering-Plough,
Kenilworth, New Jersey) 0.03 mg/kg was applied intramuscularly (IM) twice a day for 10
days postoperatively.
During the operation, the core temperature of the recipient BN rat and the hindlimb
temperature were closely monitored rectally as well as by an intramuscular temperature
probe.Themuscletemperaturewaskeptbetween28◦Cand33◦Cthroughouttheprocedure.
The rats’ core temperatures were kept between 34◦C and 37.5◦C using a heating pad and
lamp.
Shock waves
Immediately after wound closure, animals in the ESW treatment groups (groups A and E)
were exposed to 500 impulses ESW treatment at 0.19 mJ/mm2 (dermaPACE; SANUWAVE
Inc,Alpharetta,Georgia)totheentiretransplantedhindlimb(groupA)andthecontralateral
hindlimb (group E). As a contact medium, we used ultrasound transmission gel between
the ESW apparatus and the rat’s skin (Fig 1).
Experimental model
Allogeneic hindlimb transplantations from BN to LEW were carried out in 50 animals.
Animals were randomly divided into 1 of the 5 experimental groups:
Group A (n = 10), (LW → BN) received ESW locally with 500 impulses at
0.19 mJ/mm2 immediately after wound closure. Groups B, C, D, and E served as con-
trol groups with group B (n = 10) receiving no immunosuppression, group C (n = 10)
receiving FK506 (Prograft, Astellas Pharma, Munich, Germany) 0.1 mg/kg daily IM and
Prednisolone(Solu-DecortrinH; Merck Pharma,Darmstadt,Germany)0.2 mg/kgdailyIM
for 100 days, group D (n = 10) receiving no immunosuppression with isograft transplanta-
tions (BN → BN), and group E (n = 10) (LW) → BN) receiving ESW immediately after
transplantation on the contralateral hindlimb with 500 impulses at 0.19 mJ/mm2.
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Figure 1. Immediately after wound closure animals in the ESW treatment group (group A) were
exposed to 500 impulses at 0.19 mJ/mm2 (dermaPACE; SANUWAVE Inc, Alpharetta, Georgia) to
the entire hindlimb.
Postoperative monitoring
The rats were clinically assessed for their general and hindlimb condition every 8 hours by
2 surgeons. Body weight was measured 3 times daily. To avoid autocannibalism protective
collars made of plastic ﬁlm were applied to all animals. The rats were followed up until
100 days postoperatively or until rejection of the hindlimb occurred. Rats in a poor general
condition or with self-inﬂicted bites were terminated.
In the hindlimb, we assessed color, edema, skin condition, hair condition, and con-
sistency of the thigh of the hindlimb. Edema was classiﬁed into 5 grades (grade 0 = no
edema, grade 4 = maximal edema). Consistency on palpation ranged from grade 0 (soft =
normal) to grade 4 (leather-like). Clinical hindlimb rejection was deﬁned as the sequence
of a sudden edema (grades 1-2) within 8 hours on the dorsum of the foot, a subsequent
change in color away from pink and hardening of the thigh (grades 2-3). All 3 parameters
needed to be present for the deﬁnition of rejection. Both observers had to deﬁne rejection
independently. Edema of the thigh, epidermal loss, desquamation, hair loss, or blistering
were not used for the deﬁnition of the onset of rejection.
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Figure 2. (a) Representative images of histological skin analysis (group B)
on day 5 after allogeneic hindlimb transplantation with approximately 20%
necrosis (grade 1), moderate inﬁltration of inﬂammatory cells (grade 2),
and 0% regeneration (grade 0) (N2R-score). (b) Representative images of
histological skin analysis (group D) on day 50 after hindlimb transplantation
with no necrosis (grade 0), few inﬁltration of inﬂammatory cells (grade 1),
and less than 10% of regeneration (grade 1) (N2R-score).
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Histology
Besides assessing the timing of rejection by clinical observation, standardized skin and
muscle biopsies (Musculus tibialis anterior) were taken separately from the lower leg on
day 5, 10, 20, 50, and 100 or when clinical rejection was suspected. We developed a
histological score called the N2R-Score that deﬁnes 4 grades of necrosis, inﬁltration of
inﬂammatory cells and regeneration.
The necrosis was described in a semiquantitative manner with 0 showing no signs
of necrosis, 1 showing less than 50% of necrosis, 2 showing between 50% and 90% of
necrosis and 3 showing 90% and 100% of necrosis. Inﬁltration of inﬂammatory cells
such as granulocytes, macrophages, and mesenchymal proliferation was also graduated in
4 different grades with 0 showing no inﬁltration, 1 showing few inﬁltration, 2 showing
moderate inﬁltration, and 3 showing dense inﬁltration of inﬂammatory cells. Graduation
of regeneration of either skin or muscle was also assessed in 4 different grades with grade
0 showing no signs of regeneration, 1 showing less than 10% of regeneration with vital
tissue, 2 showing between 10% and 50% of regeneration, and 3 showing more than 50% of
regeneration.
Histological rejection was deﬁned as when either necrosis or inﬁltration of inﬂamma-
tory cells rose to grade 2 and the other parameter rose to grade 1 (Fig 2a). Even though
regeneration as the third parameter was always seen in the control groups, it did not help
reliably for assessing the onset of histological rejection (Fig 2b). In accordance with the
literature, histological rejection was ﬁrst seen in skin biopsies because skin is known to be
the most immunogenic component in CTA.30
Animal protection and statistics
All in vivo experiments were performed according to the German Law on the Protection of
Animals.
Data are given as the mean ± standard deviation (SD). Data were tested for normal
distribution using Shapiro-Wilk test and Kolmogorov-Smirnov test. Clinical data were
tested for signiﬁcance using unpaired t test, whereas histopathological data were tested
using paired t test. Level of signiﬁcance was determined at α = 0.05. All tests were
performed by using SAS software (SAS Institute, Inc, Cary, North Carolina).
RESULTS
In group A (n = 10) (ESW), hindlimb rejection occurred on average on day 7.12 (SD =
0.83). In detail, rejection occurred once on day 5, three times on day 7, four times on day
7.3, and twice on day 8.
In group B (n = 10) (no immunosuppression) hindlimb rejection occurred on average
onday5.49(SD=0.70).Indetail,rejectionoccurredonceonday4,twiceonday5,twiceon
day5.3,fourtimesonday6,andonceonday6.3.IngroupC(n=10)(FK506/prednisolone)
and group D (n = 10) (isograft) no hindlimb rejection occurred until termination of the
follow-up on day 100. In group E (ESW to contralateral hindlimb), hindlimb rejection
occurred on average on day 5.6 (SD = 0.53). In detail, rejection occurred twice on day 5,
three times on day 5.3, twice on day 5.7, twice on day 6, and once on day 6.7.
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Figure 3. Timing of the clinical rejection after allo-
geneic hindlimb transplantations. Group A (n = 10)
received ESW locally, group B (n = 10) served as a
control group receiving no immunosuppression. The
mean rejection/survival time is shown in days postop-
eratively. The difference is signiﬁcant between group
A and group B (t test < 0.01).
Table 1. Statistical ﬁgures.
Group A B C D E
n 1 01 01 01 01 0
Rejection 7.12 ± 0.83 5.49 ± 0.70 100 100 5.6 ± 0.53
Days of rejection in detail 5/7/7/7/ 4/5/5/5.3/ No rejection No rejection 5/5/5.3/5.3/
7.3/7.3/7.3/ 5.3/ 6/ 6/ 6/ 5.3/5.7/5.7/
7.3/8/8 6/6.3 6/6/6.7
Comparing group A and B rejection was statistically signiﬁcantly delayed using ESW
treatment (unpaired t test, P <. 01) (Fig 3, Table 1). There was no signiﬁcant difference
comparing rejection between the control groups B and E (unpaired t test, P >. 9).
HistologicalrejectionbasedontheN2R-Scorewasseeninallskinandmusclebiopsies
taken when clinical rejection was suspected. The results of the biopsies taken on day 5
showed rejection only in one animal in group A, 5 animals in group B, and 5 animals in
group E. No histological rejection was seen in group C and D.
The histological ﬁndings therefore supported the clinical ﬁndings and showed that
rejection was signiﬁcantly delayed using ESW treatment (paired t test, P <. 01).
DISCUSSION
Improving immunosuppressive therapy with the eventual goal of tolerance is a major goal
not only in CTA but in all organ transplantations. Over 10 years, after the ﬁrst allogeneic
hand transplantation overall graft and patient survival as well as functional outcome is
very promising.2,4,5,8,31-34 One graft failure in hand transplantations was reported to be due
to noncompliance.4,35 One fatality has been reported following combined hand and face
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transplantation that occurred from overwhelming sepsis presumably due to the immuno-
suppressive protocol.36,37
Stillthelifelonguseofimmunosuppressivedrugsisassociatedwithnumerouscompli-
cations including delayed wound healing, opportunistic infections, drug-related toxicities,
skin malignancies, low-grade lymphomas, lymphoproliferative disorders, and end-organ
toxicity.38
Fortheﬁrsttime,weappliedshockwavesinamicrosurgicalinvivomodelofCTA.The
aim of this study was to further investigate immunosuppressive therapies in a vascularized
model of CTA by administering ESW. We were able to show that ESW treatment signif-
icantly prolongs allograft survival compared to the control groups. Shockwave treatment
to the contralateral hindlimb did not prolong allograft survival and underlined the direct
effect of ESW on the allograft. Several studies have demonstrated the efﬁciency of ESW in
the treatment of bone fractures and tendon healing.14,15,24,25 Furthermore ESW treatment
has been shown to contribute to complete wound healing in a variety of wounds, including
burns,ischemic,traumatic,andpostoperativewounds.20,22,39,40 Whiletheexactmechanism
of ESW remains unclear, several studies state that ESW serves as mechanotransduction
and improves blood supply by vasodilatation at early stage and neovascularization at a
late stage, associated with an increased expression of angioactive factors such as Nitrogen
monoxide (NO) and Vascular Endothelial Growth Factor (VEGF). Recent results of animal
and clinical studies suggest that ESW treatment suppresses early proinﬂammatory immune
response. In a skin ﬂap model in rodents, Kuo et al41 stated that there has been a positive
effect in reducing the ischemic zones of ﬂaps by increasing tissue perfusion. In their study,
histological analysis of the ﬂap tissue demonstrated that the inﬂammatory cell inﬁltration
was attenuated immediately after ESW treatment compared with that in control group.41 In
a subsequent study, Davis et al observed a global suppression of proinﬂammatory factors in
a severe, full-thickness and highly inﬂammatory cutaneous burn wound in a murine model
4 and 24 hours after a single ESW treatment. This observation was coupled with impaired
neutrophil and macrophage migration and a subsequent suppression of proinﬂammatory
cytokines (IL-1ß, IL-6, and TNFα).28
We hypothesize that ESW is capable of modulating speciﬁc T-cell response (either
directly or via a B-cell mediated pathway) with a decrease of acute early proinﬂammatory
mediators (chemokines, cytokines, and metalloproteinases). Moreover, we assume that
ESW improves blood supply postoperatively with expression of angioactive factors in
the operative tissue that provides the minimum requirement of oxygen and nutrition for
ischemic tissue to survive.
Although our results have shown a signiﬁcant immunosuppressive effect in a rather
complex model of CTA, the immunosuppressive effect is still limited. After our evalua-
tion this may be due to different facts: One certainty is that in CTA compared to organ
transplantations different tissue types such as skin, muscles, tendons, and bones are be-
ing transplanted, with skin being known to be the most immunogenic component.5,42
Furthermore, there may be limitations regarding the interpretation of the data due to the
experimental design. First, for better understanding of the mechanisms of ESW treatment
involved in CTA, additional molecular studies should be examined at earlier time points
to clarify the improvement in tissue survival. Second, our decision for selecting one single
ESW treatment was an empirical decision, primarily based on our previous ﬂap surgery
studies and recommendations by the manufacturer.43-45
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ThisistheﬁrststudywithapplicationofESWtreatmentinCTA.Theseﬁrstpromising
results of ESW administration in CTA raise several questions and require further research
to clarify dose-effect relations, long-term effects of ESW on immune and reparative cells
and the changes in cell populations. We believe that ESW can then be used as an adjunct
to either a tolerance model or immunosuppressive model of CTA transplantation rather
than as a single agent. While clinically ESW is often preformed under anaesthesia, PACE
technology ESW treatment does not require anaesthesia, so it may easily allow more
applications postoperatively as a continuum of care if it is determined that a protocol of
ESW is beneﬁcial to CTA.
Further investigations with repeat ESW treatments to see whether multiple interven-
tions would be beneﬁcial in terms of prolonged graft survival and ESW treatment being
added to different low-dose immunosuppressive protocols in small animal studies are
ongoing and in development.
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